Safety of meningococcal group B vaccination in hospitalised premature infants
<h4>Objectives</h4> <p>To assess the risk of significant adverse events in premature infants receiving the novel 4-component group B meningococcal vaccine (4CMenB) with their routine immunisations at 2 months of age.</p> <h4>Participants, design and setting</h4>...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BMJ Publishing Group
2018
|